Bilgic-Temel A, et al. - Researchers conducted this retrospective analysis to assess the efficacy, safety of rituximab (RTX), and treatment outcomes in Turkish pediatric patients with pemphigus vulgaris (PV) and to analyze the literature. Five patients under the age of 18 and diagnosed with PV were treated with RTX and were identified in four Turkish dermatology departments. Findings suggested that RTX treatment in pediatric patients can be effective and safe to treat recalcitrant PV. RTX is an excellent therapy option for adults and pediatric patients with pemphigus with increasing evidence.